Bristol Myers Squibb (BMY)
(Delayed Data from NYSE)
$44.85 USD
+0.15 (0.34%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $44.85 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
Bristol Myers Squibb (BMY) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$56.50 | $69.00 | $40.00 | 26.40% |
Price Target
Based on short-term price targets offered by 18 analysts, the average price target for Bristol Myers Squibb comes to $56.50. The forecasts range from a low of $40.00 to a high of $69.00. The average price target represents an increase of 26.4% from the last closing price of $44.70.
Analyst Price Targets (18)
Broker Rating
Bristol Myers Squibb currently has an average brokerage recommendation (ABR) of 2.67 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 23 brokerage firms. The current ABR compares to an ABR of 2.71 a month ago based on 23 recommendations.
Of the 23 recommendations deriving the current ABR, four are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 17.39% and 4.35% of all recommendations. A month ago, Strong Buy represented 17.39%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 4 | 5 |
Buy | 1 | 1 | 0 | 0 | 0 |
Hold | 17 | 18 | 18 | 17 | 16 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 1 | 1 | 1 | 1 | 1 |
ABR | 2.67 | 2.68 | 2.71 | 2.70 | 2.60 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/25/2024 | Not Identified | Not Identified | Hold | Hold |
4/22/2024 | Cantor Fitzgerald & Co | Olivia Brayer | Hold | Hold |
4/9/2024 | Not Identified | Not Identified | Hold | Hold |
4/1/2024 | William Blair | Matt Phipps | Hold | Hold |
3/27/2024 | Guggenheim Securities | Seamus Fernandez | Hold | Hold |
2/6/2024 | Daiwa America | Narumi Nakagiri | Moderate Buy | Moderate Buy |
11/1/2023 | Berenberg Bank | Luisa Hector | Hold | Hold |
10/27/2023 | BMO Capital Markets | Evan Seigerman | Strong Buy | Hold |
10/26/2023 | SVB Securities | David Risinger | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.67 |
ABR (Last week) | 2.68 |
# of Recs in ABR | 23 |
Average Target Price | $55.82 |
LT Growth Rate | 5.00% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 76 of 252 |
Current Quarter EPS Est: | 1.73 |